Intra-Cellular gets July 31 FDA panel date on schizophrenia treatment

TIME: 8 a.m.

EVENT: Health and Human Services Department; Food and Drug Administration (F.R. Page 27783) holds a meeting of the Psychopharmacologic Drugs Advisory Committeeto discuss new drug application 209500, lumateperone tosylate capsules for oral administration, submitted by Intra-Cellular Therapies, Inc., for the treatment of schizophrenia.

DATE: July 31, 2019

LOCATION: Tommy Douglas Conference Center, 10000 New Hampshire Avenue, Ballroom, Silver Spring, Md.

CONTACT: Jay Fajiculay, 301-796-9001, PDAC@fda.hhs.gov

https://www.marketscreener.com/INTRA-CELLULAR-THERAPIES-15688919/news/Intra-Cellular-Therapies-Health-and-Human-Services-Department-Food-and-Drug-Administration-F-R-28906389/